EU Panel Backs Expanding Ribociclib Approval in HR+/HER2- Breast Cancer
The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended expanding the approval of ribociclib (Kisqali) in women with HR+/HER2-negative breast cancer to include use in combination with fulvestrant (Faslodex).
Source: OncLive